05.06.2019 • Newsanimal healthBayerDede Willams

Private Equity Eyes Bayer’s Animal Health

Private Equity Eyes Bayer’s Animal Health (c) Bayer
Private Equity Eyes Bayer’s Animal Health (c) Bayer

Private equity investors both in Europe and the US are seen to be vying with each other to buy the animal health business that Bayer has put up for sale and is expected to fetch between €6 billion and €8 billion.

The German group is selling animal health to free up resources and capital to deal with the integration of Monsanto and potentially settle US lawsuits against Monsanto’s Roundup (glyphosate) herbicide.

Names on the list already are believed to include BC Partners, Cinven, both London-based along with CVC, and Frankfurt, Germany-based Permira. The official sale process has not yet begun but could start in the next few weeks.

Analysts believe this could be one of the five largest European private equity deals since 2008. Key products are veterinary treatments for both pets and livestock, including the best-selling treatment for fleas and ticks branded as Advantage.

Sales revenue of the business concentrated to around two-thirds in Europe came in at close to €1.5 billion last year, down slightly against 2017, with and earnings up slightly.

According to the newspaper Financial Times (FT), BC Partners is exploring a bid in combination with either a rival private equity firm, a large pension fund or a sovereign wealth fund.

Unlike some of its rivals, the newspaper noted that BC has experience in animal health, having acquired VetPartners – which itself has been acquisitive of late – in August 2018.

CVC reportedly has hired advisers as it prepares a bid, while Cinven and Permira are mulling whether to team up to make an offer. Advent International is also expected to bid.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.